$14.55
-4.78-24.73%
Last update: Nov 6, 4:00 PM
Anika Therapeutics Inc
ANIKNASDAQ
Anika Therapeutics (ANIK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Anika Therapeutics (ANIK) last issued guidance on November 6, 2026 for fiscal year 2026. The company guided revenue in the range of $119.59M - $124.1M for the period.
Compared to prior guidance, Anika Therapeutics maintained its revenue forecast from a prior range of $118.46M - $124.1M.
Anika Therapeutics has issued 11 guidance updates between March 6, 2023 and November 6, 2026. During this period, the company raised its outlook 3 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.14 | $-0.01 | $-0.04 | $-0.06 |
| Actual | $0.29 | $0.42 | $0.27 | $0.31 |
| Surprise | +107.1% | +4300.0% | +775.0% | +616.7% |
| Revenue | ||||
| Estimate | $29.4M | $29.2M | $28.1M | $28.9M |
| Actual | $30.6M | $32.6M | $29.6M | $30.6M |
| Surprise | +3.93% | +11.6% | +5.23% | +6.02% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.16 | $0.17 | $0.17 | $0.05 |
| Revenue | ||||
| Consensus | $30.0M | $30.4M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 6, 2026 | $0.29 | $0.14 | 107.1 % |
| Q2 | Jul 29, 2026 | $0.42 | $-0.01 | 4300.0 % |
| Q1 | Apr 29, 2026 | $0.27 | $-0.04 | 775.0 % |
| Q4 | Feb 26, 2026 | $0.31 | $-0.06 | 616.7 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 6, 2026 | $30.59M | $29.44M | 3.93 % |
| Q2 | Jul 29, 2026 | $32.61M | $29.22M | 11.6 % |
| Q1 | Apr 29, 2026 | $29.61M | $28.14M | 5.23 % |
| Q4 | Feb 26, 2026 | $30.62M | $28.88M | 6.02 % |
